ClinicalTrials.gg
CompletedNCT05160805Updated Oct 29, 2024

A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma

A Phase 1 interventional study of ONL1204 Ophthalmic solution (Dose A) and ONL1204 Ophthalmic solution (Dose B) in Open Angle Glaucoma, sponsored by ONL Therapeutics. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by ONL Therapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Glaucoma, Open-Angle with a site in Australia — none open to participants now, 2 under way, none of them phase 3. Glaucoma, Open-Angle · Australia.

Enrollment
11th of 14
25 · median 84
Started
2022
with 2 others
Phase 1
4 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
ONL Therapeutics

Among the 14 studies in Glaucoma, Open-Angle with a site in Australia, this one is the 11th largest by enrollment, is one of 3 that started in 2022, is one of 4 in phase 1, and was the 10th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 14 studies in Glaucoma, Open-Angle with a site in Australia is open now. The open studies under Glaucoma, Open-Angle, anywhere →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Glaucoma, Open-Angle with a site in Australia as a file.
02

Study summary

The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma.

ONL1204 Ophthalmic Solution is a first-in-class inhibitor of fragment apoptosis stimulator (Fas) receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease. Apoptosis of retinal ganglion cells is associated with progressive glaucoma. Nonclinical data on ONL1204 Ophthalmic Solution suggest that ONL1204 Ophthalmic Solution may inhibit the cell death pathways in these cells.

03

Conditions studied

  • Open Angle Glaucoma

Keywords

  • Progressing
  • Glaucoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged ≥18 years old
  2. Able and willing to give and attend study visits
  3. Controlled intraocular pressure (IOP) (≤21 mmHg) in both eyes for all previous 3 visits before Screening and at Screening in both eyes
  4. Prior to screening, 3 or more Humphrey Visual Field (HVF) tests (with acceptable reliability standards) or 3 or more Optical Coherence Tomography (OCT) studies of the study eye on record
  5. Open angle glaucoma that is progressing in the study eye
  6. HVF 24-2 at Screening with acceptable reliability standards and MD scores

Exclusion criteria

Exclusion Criteria:

Considerations for either eye

  1. Best Corrected Visual Acuity (BCVA) at Screening of ≤64 letters (Snellen equivalent of worse than 20/50)
  2. Severe open angle glaucoma
  3. Glaucoma due to non-open angle causes
  4. Worse than mild non-proliferative diabetic retinopathy

    Considerations for study eye:

  5. Visual field results suggestive of another disease (eg, altitudinal field defect)
  6. Evidence of macular edema based on OCT imaging and Investigator's judgement
  7. Previous intravitreal (IVT) injections, history of retinal surgery, history of retinal laser
  8. Cataract surgery within 3 months of Screening or yttrium-aluminum-garnet capsulotomy (YAG) within 4 weeks of Screening
  9. Anticipated need for surgical or procedural intervention for glaucoma, cataract, posterior capsular opacity, refractive error, or retinal conditions during the study

    Other general exclusion criteria:

  10. The requirement for oral carbonic anhydrase inhibitors to control intraocular pressure
  11. Severe, unstable, or uncontrolled cardiovascular, diabetic, renal, or pulmonary disease, based on Investigator's judgement
  12. Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg
  13. Women who are pregnant, breastfeeding, or contemplating pregnancy during the study period and men who are contemplating contributing sperm for a biologic child during the study period
  14. Participation in other ophthalmic clinical trials or use of any other drugs or devices in either eye or systemically for 3 months before Screening (Visit 1)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Treatment Group A

    ONL1204 Ophthalmic solution (Dose A) administered by intravitreal injection

    Drug: ONL1204 Ophthalmic solution (Dose A)

  • Experimental
    Treatment Group B

    ONL1204 Ophthalmic solution (Dose B) administered by intravitreal injection

    Drug: ONL1204 Ophthalmic solution (Dose B)

  • Sham comparator
    Treatment Group C

    Sham procedure without penetrating the eye

    Procedure: Sham procedure

Interventions

  • DrugONL1204Studies of ONL1204ONL1204 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Liquid formulation administered by intravitreal (IVT) injection

  • DrugONL1204Studies of ONL1204ONL1204 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Liquid formulation administered by intravitreal (IVT) injection

  • ProcedureSham procedure

    A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of ONL1204 as assessed by AE reporting and clinical evaluations

    Adverse event reporting, ophthalmic examination to evaluate the anterior and posterior segments of the eye, best-corrected visual acuity, intraocular pressure, electroretinogram, vital signs, clinical laboratory evaluations, and ophthalmic imaging results

    Time frame: up to 39 weeks

07

Study locations

11 sites
  • Albury Eye Clinic Wodonga
    Albury, New South Wales 2640, Australia
  • Sydney Eye Surgeons
    Hurstville, New South Wales 2220, Australia
  • PersonalEYES
    Parramatta, New South Wales 2150, Australia
  • Eye Associates
    Sydney, New South Wales 2000, Australia
  • Armadale Eye Clinic
    Armadale, Victoria 3143, Australia
  • Melbourne Eye Specialists
    Fitzroy, Victoria 3065, Australia
  • North West Eye Specialists
    Gladstone Park, Victoria 3403, Australia
  • Centre for Eye Research Australia (CERA)
    Melbourne, Victoria 3002, Australia
  • Waverely Eye Clinic
    Waverley, Victoria 3150, Australia
  • Eye Institute Limited
    Remuera, Auckland 1050, New Zealand
  • Capital Eye Specialists
    Wellington, 6011, New Zealand
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Apr 2024, 23 months.

Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Dec 16, 2021
StartActual
May 2, 2022
Primary completionActual
Apr 9, 2024
CompletionActual
Apr 9, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05160805
Lead sponsor
ONL Therapeutics
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
May 2, 2022
Primary completion
Apr 9, 2024
Completion
Apr 9, 2024
Last update
Oct 29, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONL1204

Start the discussion